REFIXIA (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
REFIXIA
Date registered
Evaluation commenced
Decision date
Approval time
192 working days (255)
Active ingredients
nonacog beta pegol
Registration type
NCE/NBE
Indication
REFIXIA (solution for injection) is indicated for the treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency).